Sulfotransferase 2A1 could become a novel prognostic marker for HCC metastasis, and discovering agonists for enhancing SULT2A1 activity could be a potential therapy to suppress the metastasis of HCC. The gene discussed is SULT2A1; the disease is hepatocellular carcinoma.